Monthly Trade Recap November 5, 2026 • 7 min read • By Theo Ledger
In the first three weeks of October, ARK's actively managed ETFs sold about $500 million of stock and bought about $400 million. Here is where the money went, from ARK's own daily trade disclosures.
Covers: 1–20 October 2026
The short version
- Biggest sale: ARKG sold 5.6 million shares of Personalis (PSNL), about $90 million, over 11 trading days from 6 October. Personalis went from 4.94% of ARKG to 1.38%.
- Biggest purchase: CoreWeave (CRWV), about $51 million across ARKK and ARKW.
- The pattern: ARK sold genomics tools and testing companies and bought drug developers. It trimmed fintech and consumer apps and added AI computing, defence, nuclear and space.
The figures cover ARKK, ARKW, ARKG, ARKF, ARKQ and ARKX from 1 to 20 October 2026. Dollar amounts are estimates: net shares traded, multiplied by each stock's price in ARK's 20 October holdings file.
The biggest sales
| Stock | Sold from | Approx. value |
|---|---|---|
| Personalis (PSNL) | ARKG | −$89.6M |
| Shopify (SHOP) | ARKK, ARKW | −$45.3M |
| Robinhood (HOOD) | ARKK, ARKW | −$42.2M |
| Teradyne (TER) | ARKQ, ARKX | −$39.9M |
| Twist Bioscience (TWST) | ARKK, ARKG | −$29.3M |
| 10x Genomics (TXG) | ARKK, ARKG | −$28.9M |
| Illumina (ILMN) | ARKK | −$27.7M |
| CareDx (CDNA) | ARKG | −$26.5M |
| Palantir (PLTR) | ARKK, ARKQ, ARKW, ARKX | −$24.9M |
| Toast (TOST) | ARKF, ARKW | −$24.3M |
| DraftKings (DKNG) | ARKF, ARKW | −$23.8M |
The biggest purchases
| Stock | Bought for | Approx. value |
|---|---|---|
| CoreWeave (CRWV) | ARKK, ARKW | +$50.7M |
| Veracyte (VCYT) | ARKG, ARKK | +$29.3M |
| Recursion (RXRX) | ARKG, ARKK | +$28.6M |
| Cerebras (CBRS) | ARKK, ARKW | +$27.5M |
| BWX Technologies (BWXT) | ARKK | +$23.4M |
| Iambic Therapeutics (IAM) | ARKG (new position) | +$22.0M |
| Rocket Lab (RKLB) | ARKK, ARKQ, ARKX | +$20.7M |
| Kratos Defense (KTOS) | ARKK | +$18.4M |
| Intellia (NTLA) | ARKG, ARKK | +$13.6M |
| Nurix Therapeutics (NRIX) | ARKG | +$13.0M |
Three shifts worth noticing
Genomics: from tools to treatments
ARKG and ARKK sold about $200 million of companies that sell sequencing, lab tools and tests: Personalis, 10x Genomics, Illumina, Twist and CareDx. Over the same three weeks they bought about $90 million of drug developers, most of them using AI or gene editing: Recursion, Iambic (a new position), Nurix, Kymera (also new) and Intellia. They also bought about $29 million of the diagnostics company Veracyte.
ARK doesn't explain individual daily trades, so the reasons are inference. But the direction is clear: within genomics, money moved from the companies that sell to labs toward the companies trying to make drugs.
AI computing in, some apps out
CoreWeave and Cerebras together drew about $78 million. Meta is a split decision: ARKW bought about $26 million while ARKK sold about $17 million. On the other side, ARK sold Shopify, Robinhood, Palantir, Toast and DraftKings. ARKF sold all of its DraftKings, and ARKW sold all of its Toast and all but 198 shares of its DraftKings.
Defence, nuclear and space
ARKK added BWX Technologies, which makes nuclear components and fuel, and the defence company Kratos. Rocket Lab was bought in three funds, and Archer Aviation in three for about $12 million. The one large sale in this area was Teradyne, the chip-testing and robotics company, which fell from 6.90% of ARKQ to 4.53%.
New positions and exits
- New: Iambic Therapeutics (ARKG, now 0.98%), Kymera Therapeutics (ARKG, 0.55%) and Genius Sports (ARKF, 1.07%; ARKW already held it).
- Exited: DraftKings from ARKF, Toast from ARKW and Iridium from ARKX (0.47% at the end of September), plus small leftover lines of Alibaba and Zillow in ARKF and Alphabet's class A shares in ARKQ and ARKX.
ARKK got smaller
Separately from ARK's own trades, investors took money out of ARKK. Positions that ARK didn't trade in ARKK fell by about 16% in share count between 30 September and 20 October. That is the sign of redemptions, which shrink every holding in proportion.
This is why share counts alone overstate ARK's selling in ARKK. The tables above use ARK's trade disclosures, which record ARK's own decisions and leave out these flows.
How we measured this
The figures come from ARK's daily trade disclosures for 1 to 20 October 2026, netted per fund and per stock. Dollar values use each stock's price in ARK's 20 October holdings file (21 October for ARKW). We checked the largest moves against the change in ARK's holdings files over the same period, adjusted for fund flows. The two methods agree to within about 20%.
To follow these positions day by day, see all ARK trades combined, or the holdings pages for ARKK and ARKG.
Not investment advice. Published for informational purposes only. WhaleFilings is not affiliated with ARK Invest.